Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain protein may guide hydrocephalus treatment

NCT ID NCT05399602

Knowledge-focused Sponsor: University Hospital Hradec Kralove Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether measuring a protein called NfL in the blood or spinal fluid can help doctors manage hydrocephalus, a condition where too much fluid puts pressure on the brain. Researchers studied 41 adults with this condition to see if NfL levels relate to symptoms and treatment decisions. The goal was to learn if this test could be a useful tool, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

41 people

The number who actually took part.

Started

Dec 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * In group A: * Patients with diagnosed communicating hydrocephalus * MMSE \> 10 points * Absence of any structural laesion on MRI or CT * Accepted Informed consent * In group B: * MMSE \> 10 points * Absence of any structural laesion on MRI or CT * Accepted Informed consent * Elective spinal surgery without affecting dural sac and the spinal cord * Surgery shorter than 120 minutes of lasting the general anesthesia Exclusion Criteria: * Non-communicating hydrocephalus * Structural laesion on MRI or CT (tumour, contusion, aneurysm) * MMSE \< 10 points * Life-expectancy shorter than 1 year * Pre-existing other type of demetia (m. Alzheimer, vascular dementia) * Surgery lasting more than 120 minutes * Blood loss more than 500 ml * Opening of dural sac (liquororhea) * Adverse events during general anestesia: MAP\<60 mm Hg more than 5 minutes, arythmia with need for farmacological treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain damage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain injury Charcot-Marie-Tooth disease type 1F communicating hydrocephalus hydrocephalus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain damage General anesthetics toxicity Hydrocephalus

Contacts and locations

Locations

  • University Hospital Hradec Kralove

    Hradec Králové, 50005, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.